JABANDŽIEV, Petr, Júlia BOHOŠOVÁ, Tereza PINKASOVÁ, Lumír KUNOVSKÝ, Ondřej SLABÝ and Ajay GOEL. The Emerging Role of Noncoding RNAs in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases. Oxford University Press, 2020, vol. 26, No 7, p. 985-993. ISSN 1078-0998. Available from: https://dx.doi.org/10.1093/ibd/izaa009.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Emerging Role of Noncoding RNAs in Pediatric Inflammatory Bowel Disease
Authors JABANDŽIEV, Petr (203 Czech Republic, guarantor, belonging to the institution), Júlia BOHOŠOVÁ (703 Slovakia, belonging to the institution), Tereza PINKASOVÁ (203 Czech Republic, belonging to the institution), Lumír KUNOVSKÝ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Ajay GOEL (840 United States of America).
Edition Inflammatory Bowel Diseases, Oxford University Press, 2020, 1078-0998.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30219 Gastroenterology and hepatology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.325
RIV identification code RIV/00216224:14110/20:00115894
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1093/ibd/izaa009
UT WoS 000544164200014
Keywords in English pediatrics; inflammatory bowel disease; Crohn’s disease; ulcerative colitis; noncoding RNA; microRNA
Tags 14110213, 14110223, 14110317, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 16/7/2020 08:50.
Abstract
Prevalence of inflammatory bowel disease (IBD), a chronic inflammatory disorder of the gut, has been on the rise in recent years—not only in the adult population but also especially in pediatric patients. Despite the absence of curative treatments, current therapeutic options are able to achieve long-term remission in a significant proportion of cases. To this end, however, there is a need for biomarkers enabling accurate diagnosis, prognosis, and prediction of response to therapies to facilitate a more individualized approach to pediatric IBD patients. In recent years, evidence has continued to evolve concerning noncoding RNAs (ncRNAs) and their roles as integral factors in key immune-related cellular pathways. Specific deregulation patterns of ncRNAs have been linked to pathogenesis of various diseases, including pediatric IBD. In this article, we provide an overview of current knowledge on ncRNAs, their altered expression profiles in pediatric IBD patients, and how these are emerging as potentially valuable clinical biomarkers as we enter an era of personalized medicine.
PrintDisplayed: 10/5/2024 00:10